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Subclinical illness associated with infection is thought to reduce performance and increase production
costs in feedlot cattle, but underlying components remain largely unidentified. Vaccination is frequently
used in feedlot settings but producers lack metrics that evaluate the effectiveness of vaccination pro-
grams. The goal of this study was to determine if levels of serum neutralizing antibody titers were pre-
dictive of levels of vaccine protection in a commercial setting. During this four-year study, Angus-Nellore
steers housed in a production feedlot setting were assigned to 1 of 3 vaccine treatments: killed vaccine
(kV), modified live virus (MLV) vaccine, or no vaccine (control), and were challenged with a noncyto-
pathic 1b field strain of bovine viral diarrhea virus. Rectal temperature and levels of circulating lympho-
cytes and platelets were monitored following challenge. While no animals were diagnosed as clinically ill
with respiratory disease, indicators of disease (pyrexia, lymphopenia, and thrombocytopenia) were
observed. The MLV treatment elicited higher antibody titers to the vaccination than the kV, and calves
in the MLV treatment had higher mean titers at challenge. The year that elicited the highest antibody
response to the vaccination and the year with the lowest frequency of phenotypic responses to the chal-
lenge were not concurrent. The MLV treatment had the highest proportion, 34.68%, of animals that were
protected against the challenge regardless of the pre-challenge antibody titer and had the fewest number
of lymphopenia cases in response to the challenge. Both vaccine treatments mitigated thrombocytopenia
when compared to the control treatment, and the MLV treatment reduced lymphopenia; however, these
symptoms were not completely eliminated in vaccinated animals. Pyrexia was present in 40.11% of the
animals, but no difference in the frequency of cases between treatments was observed. Pre-challenge vac-
cination response was not indicative of the level of protection nor was anamnestic antibody response cor-
related with health status.
 2016 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Cattle infected with bovine viral diarrhea virus (BVDV) present
with a variety of clinical and subclinical symptoms determined by
the virulence of the BVDV strain and the immune status of the ani-
mal [1–4]. BVDV has been associated with respiratory disease,
reproductive failure and gastrointestinal disease [5,6], and out-
breaks reduce the productivity and economic viability of cattle
populations [7–9]. BVDV infection results in immunosuppression,predisposing cattle to secondary infections that may lead to bovine
respiratory disease (BRD) [3,5,6,10,11]. Some animals with acute
BVDV infections have subclinical symptoms making it challenging
to identify and to determine necessary protection for disease pre-
vention [12,13].
High levels of BVDV immunity are associated with protection
from disease, improved productivity, and economic benefits in
pre-feedlot animals [6]. Both humoral and cell-mediated immune
responses provide protection against respiratory infection
[11,14,15], but detectable levels of humoral and/or cell-mediated
immunity do not assure protection against infections [16–18].
While the presence of neutralizing antibodies is frequently used
as a measurement of immune response to vaccination, the thresh-
old of neutralizing antibodies required for protection against BVDV
infection is unknown [15].
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the heterogeneity among different viral strains and the unique
interaction of the virus with the host immune system [14,19],
along with genetic and individual variation of the host [19,20].
Vaccination with either a killed or modified life virus (MLV) pro-
duct is a major component of prevention programs for both persis-
tent and acute BVDV infections [21,22]. It is desirable to achieve
maximal response to vaccination at minimal physiological expense
to avoid reduced performance [23].
Numerous vaccine and challenge studies have been performed
with differences in immune responses observed, but few have been
performed in production settings to evaluate the efficacy of vacci-
nations in a commercial operation [24–26]. This is information is
important for feedlot producers as they design and evaluate vacci-
nation programs. This study was conducted in commercial produc-
tion setting over four years and utilized F2 and F3 Indicine-Taurine
steers. The goals were to determine whether (1) differences existed
in immune protection between cattle, with the same levels anti-
bodies in sera, that were vaccinated with killed or MLV vaccines;
(2) the level of serum neutralizing antibody levels following vacci-
nation were predictive of level of protection; and (3) current indus-
try metrics are adequate for identification of sick animals post-
pathogen exposure.2. Materials and methods
This project was reviewed and approved by the Texas A&M
University Institutional Animal Care and Use Committee and the
Texas A&M University Institutional Biosafety Committee.
2.1. Animal population
Angus-Nellore F2 and F3 yearling steers were used for the study.
Calves were spring-born in 2009, 2010, 2011, and 2012 and were
castrated prior to weaning. Steers were weaned at approximately
7 months of age and received 3 clostridial vaccinations with Clostri
Shield 7 (Novartis Animal Health US, Inc., Greensboro, NC) at
approximately 70 days of age, 3 weeks prior to weaning, and at
weaning. Calves did not receive any vaccines against respiratory
pathogens. Steers were tested for persistent BVDV infection at
the Texas Veterinary Medical Diagnostics Laboratory (TVMDL;
Amarillo, TX) prior to enrollment using an immunohistochemistry
or antigen-capture ELISA assay on ear notch samples. All animals in
this study tested negative for BVDV persistent infection and were
sero-negative for antibodies against BVDV types la, 1b, and 2 prior
to enrollment.
2.2. Vaccination treatments
Steers were classified by sire and randomly assigned to 1 of 3
vaccine treatments: killed vaccine (kV; n = 119), MLV vaccine
(n = 124), or control (n = 116). Animals assigned to the kV treat-
ment received Novartis Virashield 6, according to label directions,
receiving an initial dose on day -56 or -49, and a second dose
21 days later. Steers in the MLV treatment received a single dose
of Novartis Arsenal 4.1, according to label directions, on the same
day the second dose was administered to the kV treatment group.
Vaccine products were labeled for protection against BVDV 1 and 2,
infectious bovine rhinotracheitis, bovine respiratory syncytial
virus, and parainfluenza 3, specific strains for kV and MLV vaccines
(Table S1). Control treatment steers received no vaccination or
sham injection. The MLV vaccinated steers were housed in isola-
tion from the other treatment groups for 7–10 days following vac-
cination. Steers were assigned to 1 of 4 pens with treatment-sire
groups balanced across pens.2.3. Challenge
All steers were challenged, day 0, intranasally with 5 mL of
1  105 TCID50 BVDV CA401186a (2.5 mL of inoculum per nasal
passage) 25–35 days after booster vaccination. BVDV CA401186a
was obtained from USDA-ARS National Animal Disease Center,
Ames, IA [27]. The challenge strain CA0401186a was classified as
a BVDV 1b based on 50 UTR sequence comparisons [3]. When used
as a challenge strain in BVDV-free dairy calves, significant reduc-
tion in platelet counts, lymphocyte counts, and pyrexia were
observed, however severe acute BVDV was not observed [3].
2.4. Sample and data collection
Rectal temperatures were recorded on days 0, 3, 7, 10, 14, 28,
and 42 post-challenge (PC).
Sera were prepared from whole blood collected on vaccination
days, and days 0, 14, 28, and 42 PC and stored at 20 C until used.
Serum neutralizations against cytopathic BVDV strains 1a, 1b, and
2 (Table S1) were performed in duplicate on serially diluted (1:4 to
1:4096) sera by TVMDL (Amarillo, TX). The end titer was deter-
mined as base 2 log of the highest dilution that showed no cyto-
pathic effect.
Whole blood was collected in EDTA vacutainers (Becton, Dickin-
son and Company, Franklinlakes, NJ) on days 0, 7, 14, 28, and 42 PC.
Samples were shipped overnight and differential WBC counts, pla-
telets, and red blood cell characteristics were determined on blood
samples using a CELL-DYN 3700 blood analyzer (Abbott Laborato-
ries, Abbott Park, IL) at the University of Arkansas Nutrition Labo-
ratory (Fayetteville, AR).
Steers were observed for objective clinical assessment twice
daily for the first 14 days PC, and then once daily through day 42
PC, by the same trained individual for all four years of challenge
and once daily by the same licensed veterinarian. Objective clinical
assessments were recorded on a 6-point scale for each symptom:
cough, ocular and nasal secretion, depression, diarrhea, and anor-
exia [28]. Criteria for clinical diagnosis was a score >3 for a single
symptom or a combined scoreP3 for two or more symptoms. Ani-
mals with rectal temperatures over 40.0 C, regardless of clinical
scores, were treated once with tulathromycin (Zoetis, Kalamazoo,
MI) according to label directions.
2.5. Calculations and statistical analyses
Declines in lymphocytes and platelets were calculated as the
difference between the lowest circulating lymphocyte/platelet
count PC and day 0 count, divided by the count on day 0 PC and
multiplied by 100 to generate the percent decline [3]. Anamnestic
antibody response was defined as area under the curve (AUC) of
the log base 2 titers from days 0 to 42 PC, using the trapezoidal
summation method [29].
Disease phenotypes were analyzed as 2-level categorization
(healthy and sick). Pyrexia defined as an elevated rectal tempera-
ture of 1 SD greater than day 0 PC temperature for 2 or more con-
secutive collection days within 14 days PC. Lymphopenia and
thrombocytopenia, defined as >40% maximum decline. Clinical
presentation was defined by presentation of pyrexia, lymphopenia,
and thrombocytopenia. Subclinical presentation was lymphopenia
and thrombocytopenia with no pyrexia.
Response to vaccination was analyzed as antibody titers in 4
categories (no, low, mid, and high). No titer included animals with
no detectable titers post-vaccination (n = 153). Low titers wereP2
and <4 (n = 87). Mid titers were P4 and <6 (n = 87). High titers
were P6 (n = 32).
Statistical analyses were performed in SAS 9.3 (SAS Institute
Inc., Cary, NC). Mixed model analysis was used for daily rectal tem-
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Fig. 1. Antibody titers by year. Distribution of BVDV 1b antibody titers in steers at
day 0 (No: titer = 0; Low: 2 6 Titer < 4; Mid: 4 6 Titer < 6; and High: TiterP 6) to
(a) Killed Vaccine (kV) and (b) MLV vaccine by year.3. Results
3.1. Response to vaccine treatments
Response to vaccination was measured by neutralizing antibod-
ies on day 0 of the BVDV 1b challenge (25–35 days after booster
vaccination). The steers in the MLV treatment had higher 1b mean
titers for 3 out of the 4 years compared to the kV and control treat-
ments (Table 1). Highest 1b mean titers for both the kV and MLV
treatments were observed in 2010 (Table 1). The lowest mean titer
for the kV was observed in 2012, while the lowest MLV treatment
titer was observed in 2011 (Table 1). The peak type 2 titers were
observed in 2012 for both MLV and kV treatments. BVDV 1a vac-
cine titers were highest in 2012 for the MLV treatment, while
2011 had the numeric peak in the kV treatment with no statistical
significance between 2011 and 2012 (Table 1). No differences were
observed in the control treatment for all BVDV genotypes as no
detectable titers were measured in steers in the control treatment
(Table 1). Year effects were observed in all BVDV antibody titers
post-vaccination, however the year effects were different for the
two vaccine treatments (Table 1). BVDV 1b antibody titers were
higher for the MLV treatment than for the kV or control treatments,
while the mean type 2 titers were higher in the kV treatment pre-
challenge (Table 1).
The distributions of antibody titers between the two vaccine
treatments were different (Fig. 1; Fig. S1). Responses to the vacci-
nes showed a bell-shaped curve in response to the kV for all years,
while in 2010 more animals in the MLV treatment exhibited high
titers than no or low titers (Fig. 1). The kV treatment elicited more
no and low titer responses than mid and high responses (Fig. 1a).
Alternatively, the MLV treatment elicited mid and high titers with
fewer no titer responses (Fig. 1b). The titers produced by the MLV
treatment were evenly distributed with a titer of 3 at the peak of
2011 and 2013 challenge years and a peak titer of 4 in 2010 andTable 1
BVDV treatment antibody titer means. BVDV 1b average neutralizing antibody titers by ch
N BVDV 1b titer (SD)
kV
2010 28 3.29 (1.67)a
2011 33 2.73 (2.10)a,c
2012 30 1.63 (1.35)b
2013 28 2.29 (1.88)b,c
MLV
2010 25 5.64 (1.38)d
2011 34 3.00 (1.48)a
2012 33 4.45 (1.23)e
2013 32 4.16 (1.53)e
Control
2010 23 0.00 (0.00)f
2011 33 0.00 (0.00)f
2012 32 0.00 (0.00)f
2013 28 0.00 (0.00)f
Alphabetic superscripts indicate differences across years within a treatment and across2012 (Fig. S1). The 2010 response to the kV was a bell curve similar
to the response observed for the MLV treatment, however higher
numbers of no responders were observed in 2011–2013 with the
greatest proportion of the animals in those years in the no and
low response groups (Fig. S1).allenge year to the vaccination at day 0.
BVDV 1a titer (SD) BVDV 2 titer (SD)
0.96 (1.53)a 2.14 (1.74)a
2.85 (2.24)b,c 3.27 (2.13)b
2.43 (1.57)b,d 3.57 (2.16)b
1.14 (1.63)a 2.18 (2.04)a
2.32 (1.77)b,e 1.20 (1.26)c
2.03 (1.34)d,e 0.91 (1.26)c
3.33 (1.22)c 2.52 (1.42)a
1.34 (1.62)a 1.09 (1.44)c
0.00 (0.00)f 0.00 (0.00)d
0.00 (0.00)f 0.06 (0.35)d
0.09 (0.53)f 0.00 (0.00)d
0.07 (0.38)f 0.00 (0.00)d
treatments at P < 0.05 within a column (BVDV genotype).
5056 E.D. Downey-Slinker et al. / Vaccine 34 (2016) 5053–50593.2. Response to the BVDV 1b challenge
The maximum platelet decline observed was 93.6%, while
maximum lymphocyte decline was 80.6%. Animals in the control
treatment group had the greatest decline in circulating lympho-
cytes and platelets. Lymphocyte counts in animals receiving MLV
treatment declined less (P < 0.05) than in animals receiving either
the kV or control treatments (Fig. 2a). The average maximum pla-
telet decline in the MLV treatment was less than in the control
treatment (P < 0.05); the platelet decline in the kV treatment was
intermediate to MLV and control, and not statistically different
from either (Fig. 2b).
The highest individual recorded temperature in the first 14 days
PC was 41.8 C, in the control treatment. Mean day 0 temperatures
were not different among treatments; steers receiving the MLV
vaccine had lower mean rectal temperatures through day 7 PC
compared to the other treatments (P < 0.001) (Fig. 2b). No differ-
ences were observed among treatments for mean rectal tempera-
tures by day 10 PC. In addition to rectal temperature collections,
animals were observed daily for additional clinical respiratory
symptoms. No animal met the threshold for clinical illness or39.5
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Fig. 2. Lymphocyte and platelet decline and rectal temperature response to BVDV
challenge. (a) Greatest decline (%) in circulating lymphocytes and platelets by
treatment (killed vaccine (kV), modified live virus (MLV) vaccine, or control (non-
vaccinated)) post-challenge with BVDV 1b CA0401186. Data displayed as mean-
s ± SEM. Superscripts a,b represent significant differences (P < 0.001) between
treatment groups for lymphocyte decline. Superscripts y,z represent significant
differences (P < 0.05) between treatment groups for platelet decline. (b) Mean rectal
temperature by treatment (killed vaccine (kV), modified live virus (MLV) vaccine, or
control (CON; non-vaccinated)) across the first 14 days post-challenge. Significant
treatment differences within day are denoted by aP < 0.001 between MLV and kV/
Control treatments, and bP < 0.05 between MLV and kV/Control treatments.warranted additional rectal temperature measurements for
therapeutic treatment based on objective clinical assessment.
When challenged, 20.89% of the animals did not present with
pyrexia or subclinical signs. Lymphopenia was the most frequent
sign of subclinical disease (55.15%) PC. Thrombocytopenia was
observed in 40.67% of the animals and 40.11% of the animals pre-
sented with pyrexia PC. These responses varied by treatment and
year (Table 2).
3.3. Vaccine effects on response to BVDV 1b challenge
Vaccine treatment affected the response to the challenge for
most phenotypes. The MLV treatment had the greatest proportion
of animals (34.68%) without pyrexia and subclinical signs PC
(Table 2). No difference was observed in protection from the kV
treatment compared to the control treatment for prevention of
lymphopenia or no symptoms (Table 2). The MLV treatment signif-
icantly reduced (P < 0.05) the number of animals that presented
with lymphopenia to approximately half of the kV and control
treatments (Table 2). Thrombocytopenia was observed in signifi-
cantly fewer individuals (P < 0.05) receiving vaccination compared
to controls (Table 2). No treatment differences were observed in
the percentage of animals that presented with pyrexia.
3.4. Year effects of response phenotypes to BVDV 1b challenge
Year effects on response phenotypes were highly variable. The
year effect trended similarly for lymphopenia and thrombocytope-
nia. Lymphopenia and thrombocytopenia were most prevalent in
2010 (P < 0.05); approximately 70% of the animals in that year pre-
sented with reduced cell counts in response to the challenge
(Table 2). No differences were observed in lymphopenia and
thrombocytopenia prevalence in 2011–2013 (Table 2). The greatest
proportion of animals to present with no disease signs was in 2011,
and that same year showed the lowest number of steers presenting
with pyrexia in response to the challenge but not significantly dif-
ferent from 2010 levels (Table 2). The year with the highest pro-
portion of pyrexia presentation was not the same year with the
greatest proportion of steers with lymphopenia and thrombocy-
topenia (Table 2).
3.5. Titers and protection from disease
Detectable titers were found in 70.70% of the individuals with-
out symptoms PC (Fig. 3a). The MLV treatment group included sig-
nificantly more individuals with detectable titers and no disease
signs (P < 0.05), accounting for 53% of the healthy animals
(Fig. 3a). No difference in pyrexia frequency was observed between
titer levels (P > 0.05) (Fig. S2a). Animals with no detectable titers
presented with lymphopenia and thrombocytopenia at a higher
frequency than animals with detectable levels (Fig. 3b and S2b).
Lymphopenia was more frequent at high titers in the MLV treat-
ment, but was more frequent at low titer in the kV treatment
(Fig. 3b). When vaccine titers were in the low to mid range, the fre-
quency of thrombocytopenia presented less frequently than when
no titers were detectable (Fig. S2b). No treatment interaction was
observed between antibody titers post-vaccination and pyrexia
or thrombocytopenia (P > 0.05).
3.6. Clinical versus subclinical response
The frequency of lymphopenia and thrombocytopenia with pyr-
exia (clinical) and without pyrexia (subclinical) were compared
(Fig. 4a). The subclinical presentation occurred at 1.24 times as
often as clinical presentation. Subclinical disease symptoms
occurred more frequently in steers with mid to high titers. No
Table 2
Disease symptoms by treatment. Percentage of animals with (1) no disease signs (2) clinical sign of pyrexia (2 or more consecutive time points of rectal temperature >1 SD from
baseline temperature), (3) lymphopenia (>40% decline in lymphocyte counts), and (4) thrombocytopenia (>40% reduction in platelet counts) following BVDV 1b challenge by
treatment and year.
N No disease signs Pyrexia Lymphopenia Thrombocytopenia
Treatment
kV 119 16.81b 40.34 64.71b 37.82a
MLV 124 34.68a 34.68 33.87a 31.45a
Control 116 10.34b 45.69 68.10b 53.45b
Year
2010 76 10.53a 36.84b,c 71.05a 72.37a
2011 100 32.00b 25.00c 52.00b 29.00b
2012 95 20.00a 54.74a 52.63b 28.42b
2013 88 18.18a 44.32a,b 47.73b 39.77b
a,b,c Superscripts indicate differences between treatment or year within a column.
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observed in steers with no to low titers (Fig. 4a).
3.7. Anamnestic antibody response to BVDV challenge
The greatest anamnestic antibody response was observed in the
kV treatment group, by day 14 PC (Fig. 4b). Year differences in the
anamnestic response to vaccination were similar to thosedescribed for response to vaccination (not shown). The MLV treat-
ment had higher titers on day 0 in response to vaccination, but
demonstrated lower anamnestic antibody response to the chal-
lenge than the kV treatment (Fig. 4b). By day 42, no difference
was observed between the MLV and control treatment (Fig. 4b).
Anamnestic antibody response PC was not different for healthy
versus sick animals that presented with pyrexia, lymphopenia, or
thrombocytopenia or the combination (P > 0.05) (Fig. S3).
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We observed that the MLV treatment elicited higher antibody
titers compared to the kV treatment. The fact that animals in the
kV treatment group developed higher anamnestic responses com-
pared to the MLV treatment PC is probably related to greater repli-
cation of the virus in the kV groups and conversely greater
protection against viral replication in the MLV groups. These
results correlate with previous studies that found that MLV vacci-
nes elicit more robust and longer lasting immune responses com-
pared to killed vaccines, suggesting why the vaccine titers were
higher for the MLV treatment [14,23,30]. Animals that were vacci-
nated with an MLV vaccine were better protected against the chal-
lenge, especially those steers in the no, low and mid titer category.
Similar to our findings, vaccinated animals were reported to have
protection even in the absence of titers from vaccination [28]. Con-
versely, calves with lower serum neutralizing antibody levels at
entry to the feedlot have been reported to be at increased risk
for BRD treatment, illness, and reduced net value to the owner
[26]. Our results suggest that the immune response elicited by
the MLV vaccine stimulated more than a humoral antibody
response, as animals with no and low titers were better protected
than the kV treatment animals at the same titers. Furthermore,
protection against a BVDV challenge can occur in the absence of
detectable post-vaccination antibody titers [8,31], and several
studies have shown little correlation between increased antibody
titers and disease prevention [32]. Our results correspond with
others’ suggesting that the type of immune response may be more
important for protection against viral pathogens than increased
titers of neutralizing antibodies [11,33,34]: both a primed T- and
B-cell response may be required to offer optimal protection against
the challenge.
Respiratory infection in feedlots is typically diagnosed through
observed clinical assessment, and affected animals are treated
based on elevated rectal temperature [35]. However, multiple
studies have documented no observed objective clinical signs post
BVDV challenge, although leukopenia and pyrexia were reported
shortly following challenge [31,36–39]. These findings suggest that
not all BVDV infections present with visible symptoms.
Rectal temperatures were recorded on pre-determined days
rather than as a final clinical threshold following initial objective
clinical assessment, as would be the case in a field protocol. Obser-
vations of pyrexia were observed in cattle with leukopenia similar
to previous studies [16,22,37–39], but not all cattle with lympho-
cytopenia and thrombocytopenia experienced pyrexia. Based on
our data, rectal temperature is not a reliable indicator of morbidity,
and utilization of rectal temperature to identify sick cattle may
miss a portion of sub-clinically ill cattle. The presence of sub-
clinically ill, undiagnosed cattle in a population may have large
financial impacts, which are difficult for operators to directly
assess [4,40]. Assessment of disease presentation by leukopenia
and thrombocytopenia may increase the detection of ‘‘sick” ani-
mals compared to traditional observational diagnoses.
Lymphocytopenia and thrombocytopenia are subclinical indica-
tors of BVDV infection. Lymphopenia was observed in both vacci-
nated and unvaccinated calves post-challenge, with an average
reduction of 39.4% in lymphocytes following the challenge, similar
to other reports [1,3,12,34,37,41]. Large variations in circulating
lymphocyte counts among steers were observed, including calves
with lymphocytes elevated by 40% from baseline to calves with
severe lymphopenia of 80% reductions, suggesting that individual
variation exists within the population and that some calves
develop a more robust immunity for protection against the BVDV
challenge than others. Results from this study and others suggest
that a protective response from vaccination should prevent
leukopenia and thrombocytopenia during pathogen exposure [8,13].Vaccination reduced the subclinical effects of the BVDV chal-
lenge. Calves that received MLV were less susceptible to lym-
phopenia and thrombocytopenia than non-vaccinated animals,
similar to other studies [23,38,42]. The MLV treatment appeared
to elicit a more robust immunological response to protect against
lymphopenia compared to the kV treatment, although unmea-
sured. Vaccinated steers displayed less severe lymphocytopenia
and thrombocytopenia following the challenge than unvaccinated
steers, and this concept is likely important in production environ-
ments. The lower antibody titers observed in the anamnestic
response indicated that the MLV treatment had greater protection
from vaccination, which resulted in less viral replication PC. This
suggests that the MLV vaccine likely stimulated both a humoral
and cell-mediated immune response (not measured in this study).
Titers following pathogen exposure cannot be used to gauge the
level of protection within a population.
In conclusion, this study suggests that antibody titer may not be
a reliable metric of protective immune response against a BVDV 1b
challenge or of disease status. Reber et al. [32] similarly reported
weak to no correlations between humoral and cellular immune
responses, and Ridpath [31] previously suggested that level of anti-
body titers may not be a reliable indicator of level of protection.
Based on these results the titer threshold for protection is variable
and is dependent on the other immune components that have been
primed by the vaccination. To find the protection titer threshold it
may be critical to understand the type of vaccination and the
humoral immune response stimulated, as well as animal-to-
animal variation, i.e. genetics. More steers in this experiment had
lymphocytopenia and thrombocytopenia than pyrexia, suggesting
that rectal temperature does not identify all animals with
infection. Additionally, rectal temperature used alone as a predic-
tor for morbidity likely misses a substantial proportion of cattle
with BVDV infection. These results show a benefit from BVDV
vaccination even in the presence of low detectable titers, and that
the MLV vaccine provided better protection against BVDV 1b
challenge in a production setting. Undiagnosed, sub-clinically ill
animals in commercial feedlots likely present significant health
management obstacles as viral reservoirs and potential sources
of reduced production efficiency. Vaccine efficacy for commercial
use needs to be evaluated on the prevention of subclinical disease
presentation and the stimulation of both humoral and cell-
mediated arms of the immune response as antibody titers alone
do not appear to be indicative of the level of protection offered
by a vaccination.Conflict of interest
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